SLC5A2 and type 2 diabetes mellitus: In the CREDENCE trial, SGLT2 inhibitor canagliflozin reduces blood pressure independent of starting blood pressure levels and other concomitant blood pressure-lowering agents in patients with T2DM and CKD (Ye et al. 2021).